NCT05305989CompletedPhase 2
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Source: ClinicalTrials.gov · Last updated 2 May 2025
Brief summary (registry, in English)
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 2 Feb 2022
- Start date
- 23 Feb 2022
- Primary completion date
- 6 Jun 2024
- Lead sponsor
- Kadmon, a Sanofi Company
- NCT number
- NCT05305989
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 23
- From 23 Feb 2022 to the primary completion date, 6 Jun 2024
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Female subject who is pregnant or breastfeeding
- Subject considered unlikely to adhere to treatment and/or follow protocol in the opinion of the Investigator
Who the study is looking for
- Subjects must have been treated with belumosudil for at least 1 of the following:
- Actively receiving belumosudil on Study KD025-208 or Study KD025-213
- Is in Long-term Follow-up (LTFU) on Study KD025-208 or Study KD025-213. Long-term Follow-up will be defined as the period after ending treatment with belumosudil and until a FFS event occurs.
- Adult enrolled in the Companion Study under KD025-213 Amendment 2 (01 June 2020) and has received at least 6 months of treatment of belumosudil or is in LTFU
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| South Austin Medical Center Site Number : 091 Coordinator of this site? Confirm its status | Austin | United States | Unknown status |
| City of Hope Site Number : 050 Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
| MD Anderson Cancer Center Site Number : 057 Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132 Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
| Texas Transplant Institute Site Number : 079 Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| Fred Hutchinson Cancer Research Center Site Number : 052 Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
| Stanford Cancer Center Site Number : 108 Coordinator of this site? Confirm its status | Stanford | United States | Unknown status |
| Washington University School of Medicine Site Number : 125 Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.